|
|
|
prIME Oncology invites you to view exciting news released from the 2010 Oncology Annual Meeting
in Chicago.
|
|
|
 |
|
9 JUNE 2010
|
| |
|
This expert interview with Lisa Carey, MD, from the University of North Carolina Chapel Hill in Chapel Hill, North Carolina, and William J. Gradishar, MD, from Northwestern University in Chicago, Illinois, discusses the topic of breast cancer focusing on the following data releases:
#508: Prognostic and predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor (PAM50) for adjuvant tamoxifen in premenopausal breast cancer: Results from the NCIC CTG MA.12 randomized trial
#533: Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer
#CRA1004: A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane
#1005: A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC)
|
| |
|
View an expert interview and opinion with Lisa Carey, MD, and William J. Gradishar, MD 
Click here to complete the post-test online |
|
|
|
|
|
|
